Phase II Trial of XL119 (Rebeccamycin Analogue) in Relapsed 'Sensitive' Small Cell Lung Cancer.

Trial Profile

Phase II Trial of XL119 (Rebeccamycin Analogue) in Relapsed 'Sensitive' Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Becatecarin (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2014 Actual end date changed from Apr 2008 to October 2008 as reported by ClinicalTrials.gov.
    • 14 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 19 Jun 2012 Actual end date changed from May 2010 to Apr 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top